HC Wainwright Research Analysts Boost Earnings Estimates for BriaCell Therapeutics Corp. (TSE:BCT)

BriaCell Therapeutics Corp. (TSE:BCT) – Stock analysts at HC Wainwright increased their FY2024 earnings per share (EPS) estimates for shares of BriaCell Therapeutics in a report issued on Thursday, September 19th. HC Wainwright analyst E. Bodnar now forecasts that the company will post earnings per share of ($1.09) for the year, up from their prior forecast of ($1.90). HC Wainwright also issued estimates for BriaCell Therapeutics’ Q4 2024 earnings at ($0.71) EPS, FY2025 earnings at ($0.35) EPS, FY2026 earnings at ($0.33) EPS, FY2027 earnings at ($0.26) EPS and FY2028 earnings at ($0.16) EPS.

BriaCell Therapeutics Stock Down 4.4 %

BCT stock opened at C$0.87 on Monday. BriaCell Therapeutics has a twelve month low of C$0.64 and a twelve month high of C$8.65. The firm has a market cap of C$26.72 million, a PE ratio of -1.74 and a beta of 1.74. The business has a 50 day moving average of C$0.93 and a 200 day moving average of C$2.00.

BriaCell Therapeutics Company Profile

BriaCell Therapeutics Corp. operates as a Phase 3 biotechnology company transforming cancer care with its novel cellular immunotherapies. It is conducting a pivotal Phase 3 clinical trial in advanced breast cancer with its Bria-IMT in combination with an immune check point inhibitor. It is also developing personalized off-the-shelf treatments for breast cancer, prostate cancer, and other cancers.